-+ 0.00%
-+ 0.00%
-+ 0.00%

Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY

Benzinga·09/26/2024 12:41:05
Listen to the news

For the year six month period ended June 30

  Note 2024



unaudited



£'000
2023



unaudited



£'000
Revenue   - 298
Research and development costs   (2,189) (2,251)
Administrative costs   (2,034) (2,291)
Loss from operations   (4,223) (4,244)
Finance income 3 839 410
Finance expense 3 (49) (22)
Loss before tax   (3,433) (3,856)
Taxation 4 125 288
Loss for the period attributable to the owners of the parent   (3,308) (3,568)
Total comprehensive loss attributable to the owners of the parent   (3,308) (3,568)
Loss per share      
Basic and diluted loss per ordinary share – pence 5 (0.1p) (3.6)p